Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Increasing Treatment Intervals in Wet AMD

Show Description +

Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Wet AMD

Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Wet AMD

Please log in to leave a comment.

Listen as a Podcast

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now